

# Access to Medicines

3.6. Global shortage of, and access to, medicines and vaccines

3.7. Global strategy and plan of action on public health, innovation and intellectual property (GSPoA)

4.1. Global Snakebite Burden



# Background



## Towards An R&D Agreement

a Policy Brief for Member States at the  
69th World Health Assembly



Discussions on addressing failures of current R&D incentives to provide for greater public health needs **have lasted more than 13 years.**

**It is time to act.**

## 3.6. Global shortage of, and access to, medicines and vaccines

---

- Technical definitions of shortages and stockouts etc which was requested of the DG in OP3(1) of WHA69.25 and which was so contentious at WHA70 have been deferred to WHA71.
- 33 'key considerations', Triaged approach into 3 boxes
- Mentioning UNHLP recommendations and mapping WHO-activities in relation to recommendations

### 3.7. Overall Program Review of the Global strategy and plan of action on public health, innovation and IP

---

- Manages to clarify the underlying problems of the program:
  - WHO's funding crisis
  - 'vehement opposition' of the rich countries to a global fund for R&D
- Member states should support the full adoption and funding of the recommendations of the review.
- WHO should set a clear date for implementation for the refined recommendations and give a yearly progress report
- R&D Convention now!

## 3.7. GSPoA

---

- Manages to clarify the underlying problems of the program:
  - WHO's funding crisis
  - 'vehement opposition' of the rich countries to a global fund for R&D
- Member states should support the full adoption and funding of the recommendations of the review.
- WHO should set a clear and concrete agenda for the next 5 years.
- R&D Convention now!

Most important point on the agenda!



## 4.1 Global Snake Bite Burden

---

- Inclusion of Global Snakebite burden in the EB 142 is encouraging, as it was long overdue
- Situation is another symptom of a broken system of Research and Development that is centered around a market.
- Other examples include: Pandemics (Ebola), Antibiotics
- R&D Convention now!

# Issue “Fair Price”

- replaced “affordable medicines”
- We urge WHO to change the narrative and language from “fair” drug prices for pharmaceutical manufacturers to “affordable” drug prices for the people.



**FAIR PRICING FORUM**  
INFORMAL ADVISORY GROUP MEETING

# Thank you



There is no such thing as neutrality. Every actor has an interest. For the private sector it is profit. For civil society it is peoples' health.

#EB142 @PHMGLOBAL